Floatz logo

PERFLUTREN

Hepatocellular Carcinoma

University of Southern CaliforniaSmall moleculeN/ADormant
D
28/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
65/ 100

Competitive context

263 Active assets in the Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Theprubicin
RWTH Aachen University
Phase 4BB
Ethiodized Oil
RWTH Aachen University
Phase 4BB
Eloxatin
Li Qiang
Phase 4BB
Calcium folinate pentahydrate
Li Qiang
Phase 4BB
FLUOROURACILUM
Li Qiang
Phase 4BB

View all 50 →

Same molecule, other indications

PERFLUTREN is also rated in:

Recurrent Renal Cell CarcinomaDormant
B
Indicative ·
60 / 100
View asset →
asthmaDormant
B
Indicative ·
60 / 100
View asset →
Kidney CancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →